Search results
Showing 1321 to 1335 of 1877 results for do not dos
research. Any explanatory notes(if applicable) Clinicians wishing to do ultrasound-guided high‑intensity transcutaneous focused...
such interventions? - Determine the long-term effectiveness of programmes. Do children and young people who have lost or maintained...
NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .
NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .
Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)
NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus
page. Any explanatory notes(if applicable) Clinicians wanting to do transcutaneous electrical stimulation of the supraorbital nerve for...
This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS165Show all sections
Sections for QS165
- Quality statements
- Quality statement 1: Assessment of looked-after children and young people
- Quality statement 2: Assessment of care leavers
- Quality statement 3: Assessment of children and young people in contact with youth offending services
- Quality statement 4: Information and advice for adults
- Update information
- About this quality standard
This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS91Show all sections
Sections for QS91
- Quality statements
- Quality statement 1: Discussion with a named nurse specialist
- Quality statement 2: Treatment options
- Quality statement 3: Combination therapy
- Quality statement 4: Managing adverse effects of treatment
- Quality statement 5: Hormone-relapsed metastatic prostate cancer
- Update information
- About this quality standard
This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.
Show all sections
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.